{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"221"},{"groupId":"OG001","value":"221"}]}],"title":"Any treatment-emergent AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"193"}]}],"title":"Blinded study treatment-related AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"205"}]}],"title":"CHP treatment-related AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"87"}]}],"title":"Any serious adverse event (SAE)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"45"}]}],"title":"Blinded study treatment-related SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"53"}]}],"title":"CHP treatment-related SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"15"}]}],"title":"Treatment discontinuations due to AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"}]}],"title":"Treatment discontinuations due to blinded study treatment-related AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}]}],"title":"Treatment discontinuations due to CHP treatment-related AE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"226"}],"units":"Participants"}],"description":"Any untoward medical occurrence in a clinical investigational participant administered a medicinal product which does not necessarily have a causal relationship with this treatment.","groups":[{"description":"brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone brentuximab vedotin: 1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles","id":"OG000","title":"A+CHP"},{"description":"cyclophosphamide, doxorubicin, vincristine, and prednisone doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles vincristine: 1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles","id":"OG001","title":"CHOP"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Safety Analysis Set includes all patients who receive any amount of brentuximab vedotin or any component of CHOP. Treatment group will be determined using the actual treatment received, regardless of the randomization treatment assignment.","reportingStatus":"POSTED","timeFrame":"Up to 8.28 months","title":"Incidence of Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"Participants"}